Browse diseases

…DPN-CAR T cell and GD2-CAR T cell blend to target heterogeneous GBM.Methods Target antigen screening included clinical samples, cel…

… (GBM) have been reported. For CAR-T cell therapy to succeed in GBM, several challenges must be overcome, including the immunosuppr…

…IL12) payload. These cells were tested in syngeneic, orthotopic GBM mouse models exhibiting heterogeneous EGFRvIII expression. CAR …

…in two patients with astrocytoma and c.676C>T in a patient with oligodendroglioma, corresponding to the most prevalent CNS tumour histopathology …

… bevacizumab-SIACI, 7 with ndGBM bevacizumab-SIACI, and 22 with ndGBM cetuximab-SIACI. In 133 of 139 SIACIs (95.7%), patients were di…

…Background The effectiveness of immunotherapies against glioblastoma (GB) remains limited. A major obstacle in advancing new strateg…

…. In immunocompetent mouse models bearing orthotopic, syngeneic GBM transduced with mPIIB or an empty virus, animals were randomize…

…al for management of human subjects developing CRS on study for glioblastoma (NCT04573140) and osteosarcoma patients (NCT05660408)Conclusion…

…Background Glioblastoma (GBM) remains an aggressive, lethal form of brain cancer. Curre…

…conductive to immune evasion, which is a hallmark of aggressive GBM…

…le-cell RNA sequencing and immunohistochemistry. C57BL/6 murine GBM models (CT-2A, SB28) were used to define mechanisms associated …

…Background Glioblastoma (GBM) poses significant challenges for CAR-T therapy due to ant…